AR and prostate cancer: To identify factors that selectively bind the agonist conformation of AR, we introduced Flag epitope-tagged wild-type (WT) AR into PC3 prostate cancer cells, treated the cells with an androgen agonist (R1881), and at multiple timepoints (0–24 h), isolated AR by immunoprecipitation (IP).